Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions

被引:13
作者
Motoya, T
Thevanayagam, LN
Blaschke, TF
Au, S
Stone, JA
Jayewardene, AL
Chi, J
Aweeka, FT
机构
[1] Univ Calif San Francisco, Dept Clin Pharm, Drug Res Unit, San Francisco, CA 94143 USA
[2] Kagoshima Univ, Fac Med, Dept Clin Pharm, Kagoshima 890, Japan
[3] Stanford Univ, Sch Med, Dept Med, Div Clin Pharmacol, Stanford, CA USA
关键词
albumin; M8; metabolite; nelfinavir; plasma protein binding; alpha 1-acid glycoprotein;
D O I
10.1111/j.1468-1293.2006.00356.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives To determine the characteristics of the binding of nelfinavir and active M8 to alpha(1)-acid glycoprotein (AAG) and human serum albumin (HSA), and to examine the displacement effects of drugs binding extensively to AAG (ritonavir and saquinavir) or to HSA (salicylic acid and valproic acid). Methods Free drugs were separated by equilibrium dialysis after incubation with human plasma or purified plasma proteins and after co-incubation with potential displacers. Association constants were estimated from double-reciprocal plots of the data. Results Nelfinavir and M8 free fractions [fractions of unbound drug (fus)] were 0.42 +/- 0.08% (mean +/- standard deviation) and 0.64 +/- 0.07%, respectively. For the two analytes, respectively, association constants were 7.25 x 10(7)/M and 3.33 x 10(7)/M for AAG and 1.11 x 10(6)/M and 7.92 x 10(5)/M for HSA. Nelfinavir fu in an AAG solution was significantly (P < 0.01) increased by the addition of ritonavir or saquinavir, whereas it was unaltered by addition of these drugs to whole plasma. Similarly, fu in an HSA solution was significantly increased (P < 0.01) by the addition of salicylic acid or valproic acid, whereas there was no difference in the free fraction in plasma. Conclusions The affinity of nelfinavir for human plasma proteins was higher than that of M8, and both nelfinavir and M8 showed higher affinity to AAG than to HSA. The free fraction of nelfinavir was not affected by drugs that bind extensively to AAG or albumin when these drugs were added to whole plasma in combination, suggesting a compensatory effect of alternate binding proteins.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 23 条
[1]  
AGEMURA H, 2000, J APPL THER RES, V3, P19
[2]   Nelfinavir - An update on its use in HIV infection [J].
Bardsley-Elliot, A ;
Plosker, GL .
DRUGS, 2000, 59 (03) :581-620
[3]   Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].
Barry, M ;
Gibbons, S ;
Back, D ;
Mulcahy, F .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209
[4]   REDUCTION OF THE IN-VITRO ACTIVITY OF A77003, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE, BY HUMAN SERUM ALPHA(1) ACID GLYCOPROTEIN [J].
BILELLO, JA ;
BILELLO, PA ;
PRICHARD, M ;
ROBINS, T ;
DRUSANO, GL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :546-551
[5]   Human serum alpha(1) acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease [J].
Bilello, JA ;
Bilello, PA ;
Stellrecht, K ;
Leonard, J ;
Norbeck, DW ;
Kempf, DJ ;
Robins, T ;
Drusano, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1491-1497
[6]   In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite [J].
Chaput, AJ ;
DAmbrosio, R ;
Morse, GD .
ANTIVIRAL RESEARCH, 1996, 32 (02) :81-89
[7]   Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography tandem mass spectrometry: important factors for method optimization [J].
Herforth, C ;
Stone, JA ;
Jayewardene, AL ;
Blaschke, TF ;
Fang, F ;
Motoya, T ;
Aweeka, FT .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 15 (02) :185-195
[8]   PROTEIN-BINDING OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR KNI-272 AND ALTERATION OF ITS IN-VITRO ANTIRETROVIRAL ACTIVITY IN THE PRESENCE OF HIGH-CONCENTRATIONS OF PROTEINS [J].
KAGEYAMA, S ;
ANDERSON, BD ;
HOESTEREY, BL ;
HAYASHI, H ;
KISO, Y ;
FLORA, KP ;
MITSUYA, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :1107-1111
[9]  
KAWACHI A, 1998, J APPL THER RES, V2, P101
[10]  
Kiriyama A, 1996, BIOPHARM DRUG DISPOS, V17, P739